Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is becoming increasingly more common. Treatment for PDAC is dependent not only on stage at diagnosis, but complex anatomical relationships. Recently, the therapeutic approach to this disease has shifted from upfront surgery for technically resectable lesions t...

Full description

Bibliographic Details
Main Authors:	Seifeldin Awad, Ahmad M. Alkashash, Magi Amin, Samantha J. Baker, J. Bart Rose
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-05-01
Series:	Frontiers in Oncology
Subjects:	pancreatic duct adenocarcinoma (PDAC) neoadjuvant chemotheraphy CA 19-9–carbohydrate antigen 19-9 biomarker (development) tumor biomarker
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.00620/full

Similar Items

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
by: Shreya Mehta, et al.
Published: (2021-07-01)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
by: Shreya Mehta, et al.
Published: (2021-10-01)

Metastatc Gastric Adenocarcinoma Cancer With a Very High Serum Carbohydrate Antgen 19-9 Level: A Case Study
by: Alireza Jafarinezhad, et al.
Published: (2021-05-01)

Prediction of biomarker signatures and therapeutic agents from blood sample against Pancreatic Ductal Adenocarcinoma (PDAC): A network-based study
by: Md Asad Ullah, et al.
Published: (2020-01-01)

Difference between carbohydrate antigen 19‐9 and fluorine‐18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual‐center study
by: Hirofumi Akita, et al.
Published: (2021-05-01)

Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients
by: Shuichi Aoki, et al.
Published: (2019-03-01)

Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
by: Leilani Lakemeyer, et al.
Published: (2021-03-01)

Early Diagnosis of Pancreatic Cancer: The Key for Survival
by: Gina Gheorghe, et al.
Published: (2020-10-01)

Biomarkers in pancreatic adenocarcinoma: current perspectives
by: Swords DS, et al.
Published: (2016-12-01)

Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges
by: Alex Root, et al.
Published: (2018-03-01)

Carbohydrate Antigen 19-9-Positive Gastric Adenocarcinoma: Autopsy Findings and Review of the Literature
by: Tan Wang, et al.
Published: (2017-09-01)

Improved Survival after Administration of Neoadjuvant Chemotherapy in Patients with Clinical Stage I/II Pancreatic Ductal Adenocarcinoma
by: Hendrix, Ryan J.
Published: (2019)

Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma
by: Keinosuke Ishido, et al.
Published: (2021-01-01)

Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities
by: Julie Dardare, et al.
Published: (2021-07-01)

Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0–I after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
by: Song JY, et al.
Published: (2018-08-01)

Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
by: Woohyung Lee, et al.
Published: (2020-05-01)

Evaluation the Sensitivity and Specificity of CA 19-9 Test in Gastric Adenocarcinoma
by: Mohammad Jafari
Published: (2006-06-01)

Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
by: Benjamin M. MacCurtain, et al.
Published: (2021-06-01)

CA19-9-Producing early gastric adenocarcinoma arising in hyperplastic foveolar polyp: a very unique resection case
by: Guo Xin, et al.
Published: (2011-11-01)

Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer
by: Jiayu Zhang, et al.
Published: (2020-02-01)

Molecular biological characterisation of resectable pancreatic ductal adenocarcinoma
by: Hoyer, Kaja
Published: (2021)

Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC)
by: Petra Radulović, et al.
Published: (2018-08-01)

Role of Urinary and Serum Carbohydrate Antigen 19-9 as a Biomarker in Diagnosis of Adult Giant Hydronephrosis
by: Indraneel Banerjee, et al.
Published: (2016-09-01)

An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma
by: Grasieli de Oliveira, et al.
Published: (2020-03-01)

Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma
by: Abdulrahman, O., et al.
Published: (2022)

CA19-9-producing esophageal adenocarcinoma originating from the esophageal cardia of the mid-thoracic esophagus: a case report
by: Naoki Kuwayama, et al.
Published: (2021-07-01)

Gastric Cancer with a Very High Serum CA 19-9 Level
by: Kazuya Kato, et al.
Published: (2011-04-01)

CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma
by: Rosa Coelho, et al.
Published: (2017-02-01)

Preoperative maximum standardized uptake value and carbohydrate antigen 19–9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma
by: Xinjin Gu, et al.
Published: (2019-05-01)

Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
by: Wu C, et al.
Published: (2020-03-01)

Lanthanide-Doped Upconversion-Linked Immunosorbent Assay for the Sensitive Detection of Carbohydrate Antigen 19-9
by: Chaohui Zhou, et al.
Published: (2021-02-01)

Chronic Oxaliplatin-Based Chemotherapy in a Primary Ampullary Adenocarcinoma Patient without Significant Peripheral Neuropathy: Case Report and Literature Review
by: Nedal Bukhari, et al.
Published: (2017-06-01)

Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9
by: Roman O. Kowalchuk, et al.
Published: (2021-05-01)

Updates in Anthracycline-Mediated Cardiotoxicity
by: Canan G. Nebigil, et al.
Published: (2018-11-01)

Rare primary peritoneal mucinous adenocarcinoma in a 69‐year‐old man
by: Fumiko Satoh, et al.
Published: (2021-09-01)

High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma
by: Dong-jin Wu, et al.
Published: (2018-10-01)

Diagnostic Significance of Serum IgG Galactosylation in CA19-9-Negative Pancreatic Carcinoma Patients
by: Ailing Zhong, et al.
Published: (2019-02-01)

Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker
by: Le Qin, et al.
Published: (2017-08-01)

A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples
by: Jie Hu, et al.
Published: (2021-03-01)

Serum insulin‐like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma‐associated malnutrition and muscle wasting
by: Jie Dong, et al.
Published: (2021-06-01)